8-K: Neurocrine Extends Strategic Advisor Role for Dr. Eiry Roberts
Employment Agreement Amendment
Neurocrine Biosciences, Inc. has extended the employment agreement for Dr. Eiry W. Roberts as Strategic Advisor through December 31, 2026.
Summary
- Neurocrine Biosciences, Inc. (the Company) entered into an amendment to the Amended and Restated Employment Agreement with Dr. Eiry W. Roberts, effective November 21, 2025.
- The amendment extends Dr. Roberts' term of employment as Strategic Advisor for an additional 12-month period, now expiring on December 31, 2026.
- Dr. Roberts previously served as Chief Medical Officer until June 2, 2025, when she transitioned to Strategic Advisor through December 31, 2025.
- Her base salary for 2025 is set at an annual rate of $731,400.
- For 2026, Dr. Roberts' base salary will be established by the Compensation Committee after considering the CEO's recommendation.
- Dr. Roberts is eligible for an annual cash incentive bonus for calendar years 2025 and 2026, with a target of 60% of her base pay, based on corporate goals and individual performance.
- If the agreement expires on December 31, 2026, without earlier termination, Dr. Roberts will not be entitled to any Severance Benefits.
Sentiment
Score: 6
Explanation: Slightly positive, as it indicates the retention of an experienced executive in an advisory capacity, which can be beneficial for strategic continuity. No significant negative financial implications are immediately apparent.
Positives
- Retains an experienced former Chief Medical Officer, Dr. Eiry W. Roberts, as a Strategic Advisor for an extended period, ensuring continuity of expertise.
- Provides stability in strategic guidance through December 31, 2026.
Negatives
- The specific financial impact of the extended advisory role beyond 2025, particularly the 2026 base salary, is not yet determined and will be set by the Compensation Committee.
Future Outlook
The company will continue to benefit from Dr. Eiry W. Roberts' strategic advice through the end of 2026. Her compensation for 2026, specifically the base salary, will be determined by the Compensation Committee.
Management Comments
- The Company and Dr. Roberts mutually agreed to extend her employment as Strategic Advisor, reflecting a continued desire for her contributions.
Industry Context
In the highly competitive biopharmaceutical industry, retaining experienced leadership and scientific expertise, even in advisory capacities, is a common strategy to maintain institutional knowledge and strategic continuity, especially for companies with ongoing R&D pipelines and commercial products like Neurocrine Biosciences.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Strategic Advisor | Eiry W. Roberts, M.D. (term ending Dec 31, 2025) | Eiry W. Roberts, M.D. (term extended to Dec 31, 2026) | November 21, 2025 | Extension of employment agreement |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Employment Agreement Amendment | Amendment to the Amended and Restated Employment Agreement with Dr. Eiry W. Roberts, extending her term as Strategic Advisor and detailing compensation terms for the extended period. | November 21, 2025 | Ensures continued strategic guidance from a former key executive and clarifies compensation structure for the extended advisory role. |
Stakeholder Impact
- Shareholders: Benefit from the continued strategic insights and experience of Dr. Eiry W. Roberts, potentially contributing to long-term company strategy and performance.
- Employees: The extension of an advisory role for a former CMO may signal stability in leadership and strategic direction.
Next Steps
- Dr. Eiry W. Roberts will continue to serve as Strategic Advisor until December 31, 2026.
- The Compensation Committee will establish Dr. Roberts' base salary for 2026 after January 1, 2026.
- The Compensation Committee will determine annual incentive bonuses for 2025 and 2026 based on corporate and individual performance.
Key Dates
| Date | Description |
|---|---|
| May 30, 2025 | Date of the original Amended and Restated Employment Agreement with Dr. Roberts. |
| June 2, 2025 | Effective date of Dr. Sanjay Keswani succeeding Dr. Roberts as Chief Medical Officer; Dr. Roberts began serving as Strategic Advisor. |
| November 21, 2025 | Date of the Amendment to the Amended Employment Agreement, extending Dr. Roberts' term. |
| November 24, 2025 | Date the Form 8-K was signed by Neurocrine Biosciences, Inc. |
| December 31, 2025 | Original expiration date of Dr. Roberts' Strategic Advisor term; end of the period for which her base salary of $731,400 is fixed. |
| January 1, 2026 | Date after which Dr. Roberts' base salary will be established by the Compensation Committee. |
| December 31, 2026 | New expiration date for Dr. Roberts' employment as Strategic Advisor. |
Keywords
Neurocrine Biosciences, NBIX, Employment Agreement, Strategic Advisor, Eiry W. Roberts, Chief Medical Officer, Corporate Governance, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.